Why the study?
Do factor Xa inhibitors reduce cardiovascular events in patients with acute coronary syndrome?
Do factor Xa inhibitors reduce cardiovascular events in patients with acute coronary syndrome?
Factor Xa inhibitors represent an emerging therapeutic strategy for preventing coronary thrombosis and reducing cardiovascular events in patients with acute coronary syndrome.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Santos‐Gallego et al. (2014) conducted a review in Acute coronary syndrome. Factor Xa inhibitors (rivaroxaban, apixaban, darexaban, otamixaban) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from European Heart Journal Supplements